Drug Profile
Research programme: chronic obstructive pulmonary disease therapeutics - Seoul Pharma
Alternative Names: SPC-702Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator POSTECH; Seoul Pharma
- Developer Seoul Pharma
- Class Peptides
- Mechanism of Action Formyl peptide receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in South Korea
- 08 Oct 2015 Preclinical trials in Chronic obstructive pulmonary disease in South Korea (unspecified route)